276 related articles for article (PubMed ID: 12912964)
1. Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice.
Kozar K; Kamiński R; Switaj T; Ołdak T; Machaj E; Wysocki PJ; Mackiewicz A; Lasek W; Jakóbisiak M; Gołab J
Clin Cancer Res; 2003 Aug; 9(8):3124-33. PubMed ID: 12912964
[TBL] [Abstract][Full Text] [Related]
2. Subtherapeutic doses of interleukin-15 augment the antitumor effect of interleukin-12 in a B16F10 melanoma model in mice.
Lasek W; Golab J; Maśliński W; Switaj T; Bałkowiec EZ; Stokłosa T; Giermasz A; Malejczyk M; Jakóbisiak M
Eur Cytokine Netw; 1999 Sep; 10(3):345-56. PubMed ID: 10477391
[TBL] [Abstract][Full Text] [Related]
3. Potentiated antitumor effects of interleukin 12 and interferon alpha against B16F10 melanoma in mice.
Dabrowska A; Giermasz A; Gołab J; Jakóbisiak M
Neoplasma; 2001; 48(5):358-61. PubMed ID: 11845979
[TBL] [Abstract][Full Text] [Related]
4. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
[TBL] [Abstract][Full Text] [Related]
5. Splenic NK1.1-negative, TCR alpha beta intermediate CD4+ T cells exist in naive NK1.1 allelic positive and negative mice, with the capacity to rapidly secrete large amounts of IL-4 and IFN-gamma upon primary TCR stimulation.
Moodycliffe AM; Maiti S; Ullrich SE
J Immunol; 1999 May; 162(9):5156-63. PubMed ID: 10227987
[TBL] [Abstract][Full Text] [Related]
6. Early production of IL-4 and induction of Th2 responses in the lymph node originate from an MHC class I-independent CD4+NK1.1- T cell population.
von der Weid T; Beebe AM; Roopenian DC; Coffman RL
J Immunol; 1996 Nov; 157(10):4421-7. PubMed ID: 8906817
[TBL] [Abstract][Full Text] [Related]
7. Age-associated rapid and Stat6-independent IL-4 production by NK1-CD4+8- thymus T lymphocytes.
Chen YT; Chen FL; Kung JT
J Immunol; 1999 Nov; 163(9):4747-53. PubMed ID: 10528173
[TBL] [Abstract][Full Text] [Related]
8. Potentiatied antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo.
Goł b J; Zagozdzon R; Kamiński R; Kozar K; Gryska K; Izycki D; Mackiewicz A; Stokłosa T; Giermasz A; Lasek W; Jakóbisiak M
Leukemia; 2001 Apr; 15(4):613-20. PubMed ID: 11368364
[TBL] [Abstract][Full Text] [Related]
9. Liver NK1.1+ CD4+ alpha beta T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis.
Takeda K; Seki S; Ogasawara K; Anzai R; Hashimoto W; Sugiura K; Takahashi M; Satoh M; Kumagai K
J Immunol; 1996 May; 156(9):3366-73. PubMed ID: 8617962
[TBL] [Abstract][Full Text] [Related]
10. In susceptible mice, Leishmania major induce very rapid interleukin-4 production by CD4+ T cells which are NK1.1-.
Launois P; Ohteki T; Swihart K; MacDonald HR; Louis JA
Eur J Immunol; 1995 Dec; 25(12):3298-307. PubMed ID: 8566015
[TBL] [Abstract][Full Text] [Related]
11. Protective effect of NK1.1(+) T cells as well as NK cells against intraperitoneal tumors in mice.
Kawamura T; Seki S; Takeda K; Narita J; Ebe Y; Naito M; Hiraide H; Abo T
Cell Immunol; 1999 May; 193(2):219-25. PubMed ID: 10222065
[TBL] [Abstract][Full Text] [Related]
12. A critical role for IL-18 in the proliferation and activation of NK1.1+ CD3- cells.
Tomura M; Zhou XY; Maruo S; Ahn HJ; Hamaoka T; Okamura H; Nakanishi K; Tanimoto T; Kurimoto M; Fujiwara H
J Immunol; 1998 May; 160(10):4738-46. PubMed ID: 9590219
[TBL] [Abstract][Full Text] [Related]
13. NK1.1+ CD4+ CD8- thymocytes with specific lymphokine secretion.
Arase H; Arase N; Nakagawa K; Good RA; Onoé K
Eur J Immunol; 1993 Jan; 23(1):307-10. PubMed ID: 8419184
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses.
Griffith TS; Kawakita M; Tian J; Ritchey J; Tartaglia J; Sehgal I; Thompson TC; Zhao W; Ratliff TL
J Natl Cancer Inst; 2001 Jul; 93(13):998-1007. PubMed ID: 11438565
[TBL] [Abstract][Full Text] [Related]
15. Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer.
Yu B; Kusmartsev S; Cheng F; Paolini M; Nefedova Y; Sotomayor E; Gabrilovich D
Clin Cancer Res; 2003 Jan; 9(1):285-94. PubMed ID: 12538481
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.
Parihar R; Nadella P; Lewis A; Jensen R; De Hoff C; Dierksheide JE; VanBuskirk AM; Magro CM; Young DC; Shapiro CL; Carson WE
Clin Cancer Res; 2004 Aug; 10(15):5027-37. PubMed ID: 15297404
[TBL] [Abstract][Full Text] [Related]
17. The role of intrahepatic CD8+ T cell trapping and NK1.1+ cells in liver-mediated immune regulation.
Shibolet O; Alper R; Zolotarov L; Trop S; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Clin Immunol; 2004 Apr; 111(1):82-92. PubMed ID: 15093555
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response.
Yajima T; Nishimura H; Wajjwalku W; Harada M; Kuwano H; Yoshikai Y
Int J Cancer; 2002 Jun; 99(4):573-8. PubMed ID: 11992548
[TBL] [Abstract][Full Text] [Related]
19. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
20. CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice.
Switaj T; Jalili A; Jakubowska AB; Drela N; Stoksik M; Nowis D; Basak G; Golab J; Wysocki PJ; Mackiewicz A; Sasor A; Socha K; Jakóbisiak M; Lasek W
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4165-75. PubMed ID: 15217954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
